2025 Q4 -tulosraportti
TänäänÄänite tulossa
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
1 064
Myynti
Määrä
1 424
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 256 | AVA | EAG | ||
| 54 | AVA | EAG | ||
| 2 946 | AVA | NON | ||
| 154 | NON | NON | ||
| 10 | AVA | NON |
Ylin
20VWAP
Alin
17,04VaihtoMäärä
0,4 21 408
VWAP
Ylin
20Alin
17,04VaihtoMäärä
0,4 21 408
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 12 031 | 6 147 | +5 884 | 3 719 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| EAG | 0 | 609 | −609 | 0 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 116 | 5 010 | −4 894 | 114 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| EAG | 0 | 609 | −609 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sitten · MuokattuThe report showed as it should last year's results/economy and milestones,. That's what the report is for, isn't it..? You already know what happened last year and how the economy stands. Why are you dreaming of something else in the report? That would have been nice, yes. New year has started and we are waiting for new news for 2026. Gl guys, this will be the most exciting year in prolight. Btw :Hope these levels hold until I get paid
·11 t sittenSo, the constant delays!!! How do people manage to endure? Sometimes it's probably about waiting for results that might be worth it in the end, but honestly: patience is really put to the test.
·5 t sitten3kr! Then I can probably add to the holding, many crumbs…..
·13 t sittenFrom the report: - Following the delivery of the commercial prototypes, we carried out targeted design and production improvements during the autumn to optimize assembly processes and reproducibility. The year concluded with an important milestone when we achieved freezing of assay design for the cassette, which confirmed that the assay chemistry met the requirements for verification, validation, and pilot production. This milestone also led to more structured and forward-looking discussions with several potential partners. With freezing of assay design achieved for the cartridge, a strengthened balance sheet, and clearly defined next steps, we enter 2026 with a focus on final system verification, validation of production processes, pilot production of cartridges and instruments, followed by the initiation of the European multi-center clinical performance study. These activities represent the final and crucial steps before commercial launch in 2027. I would like to express my sincere thanks to our employees, our development and production partners, and our shareholders for their support during an important year for Prolight. We have significantly reduced technical risk, strengthened our IP position, delivered on our commitments, and strategically positioned the company for potential partnerships and future commercialization. With a clear and realistic timeline, we are now guiding Psyros through the final clinical performance study and further to market, creating value for patients, healthcare, society, and our shareholders.
·12 t sittenGood that you take social responsibility and act as the devil's advocate, Fjalle. You have taken this task very seriously in a dozen other companies too, I have seen, almost as if one would think you profited from it 😂·11 t sittenWho knows, today one can make money on all sorts of things😂- ·1 päivä sittenReport tomorrow. Exciting to hear if further development is on track without delays. Wish to hear more about clinical start-up and about possible partner discussions. The signals have probably been quite clear that the discussions have been taken to a new step and that they want a partner in the clinical process. It can be exciting going forward now. It is also the next 6 months ahead that will most likely be decisive for Prolight. An emission that Fjall here tries to scare some small investors with, I have little faith in, given the statements that have come from the management and simultaneously the insider purchases. Time will show·14 t sittenDystopian as usual from Fjall😊 everyone knows that biotech is risk and there are no guarantees for anything at all. There can be share issues and there can be agreements. Prolight must have more capital before they are finished, but it is typical that such companies either get a partner or are acquired when they have come as far as PD. We don't know this, but we know that there is great interest and we know that PD is beyond trivial talk. This is evident from what has been communicated. We also know that PD is unique with its product. I hope for the best but will be able to withstand a bucket of cold water for a while longer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
TänäänÄänite tulossa
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuThe report showed as it should last year's results/economy and milestones,. That's what the report is for, isn't it..? You already know what happened last year and how the economy stands. Why are you dreaming of something else in the report? That would have been nice, yes. New year has started and we are waiting for new news for 2026. Gl guys, this will be the most exciting year in prolight. Btw :Hope these levels hold until I get paid
- ·11 t sittenSo, the constant delays!!! How do people manage to endure? Sometimes it's probably about waiting for results that might be worth it in the end, but honestly: patience is really put to the test.·5 t sitten3kr! Then I can probably add to the holding, many crumbs…..
- ·13 t sittenFrom the report: - Following the delivery of the commercial prototypes, we carried out targeted design and production improvements during the autumn to optimize assembly processes and reproducibility. The year concluded with an important milestone when we achieved freezing of assay design for the cassette, which confirmed that the assay chemistry met the requirements for verification, validation, and pilot production. This milestone also led to more structured and forward-looking discussions with several potential partners. With freezing of assay design achieved for the cartridge, a strengthened balance sheet, and clearly defined next steps, we enter 2026 with a focus on final system verification, validation of production processes, pilot production of cartridges and instruments, followed by the initiation of the European multi-center clinical performance study. These activities represent the final and crucial steps before commercial launch in 2027. I would like to express my sincere thanks to our employees, our development and production partners, and our shareholders for their support during an important year for Prolight. We have significantly reduced technical risk, strengthened our IP position, delivered on our commitments, and strategically positioned the company for potential partnerships and future commercialization. With a clear and realistic timeline, we are now guiding Psyros through the final clinical performance study and further to market, creating value for patients, healthcare, society, and our shareholders.·12 t sittenGood that you take social responsibility and act as the devil's advocate, Fjalle. You have taken this task very seriously in a dozen other companies too, I have seen, almost as if one would think you profited from it 😂·11 t sittenWho knows, today one can make money on all sorts of things😂
- ·1 päivä sittenReport tomorrow. Exciting to hear if further development is on track without delays. Wish to hear more about clinical start-up and about possible partner discussions. The signals have probably been quite clear that the discussions have been taken to a new step and that they want a partner in the clinical process. It can be exciting going forward now. It is also the next 6 months ahead that will most likely be decisive for Prolight. An emission that Fjall here tries to scare some small investors with, I have little faith in, given the statements that have come from the management and simultaneously the insider purchases. Time will show·14 t sittenDystopian as usual from Fjall😊 everyone knows that biotech is risk and there are no guarantees for anything at all. There can be share issues and there can be agreements. Prolight must have more capital before they are finished, but it is typical that such companies either get a partner or are acquired when they have come as far as PD. We don't know this, but we know that there is great interest and we know that PD is beyond trivial talk. This is evident from what has been communicated. We also know that PD is unique with its product. I hope for the best but will be able to withstand a bucket of cold water for a while longer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
1 064
Myynti
Määrä
1 424
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 256 | AVA | EAG | ||
| 54 | AVA | EAG | ||
| 2 946 | AVA | NON | ||
| 154 | NON | NON | ||
| 10 | AVA | NON |
Ylin
20VWAP
Alin
17,04VaihtoMäärä
0,4 21 408
VWAP
Ylin
20Alin
17,04VaihtoMäärä
0,4 21 408
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 12 031 | 6 147 | +5 884 | 3 719 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| EAG | 0 | 609 | −609 | 0 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 116 | 5 010 | −4 894 | 114 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| EAG | 0 | 609 | −609 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
TänäänÄänite tulossa
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuThe report showed as it should last year's results/economy and milestones,. That's what the report is for, isn't it..? You already know what happened last year and how the economy stands. Why are you dreaming of something else in the report? That would have been nice, yes. New year has started and we are waiting for new news for 2026. Gl guys, this will be the most exciting year in prolight. Btw :Hope these levels hold until I get paid
- ·11 t sittenSo, the constant delays!!! How do people manage to endure? Sometimes it's probably about waiting for results that might be worth it in the end, but honestly: patience is really put to the test.·5 t sitten3kr! Then I can probably add to the holding, many crumbs…..
- ·13 t sittenFrom the report: - Following the delivery of the commercial prototypes, we carried out targeted design and production improvements during the autumn to optimize assembly processes and reproducibility. The year concluded with an important milestone when we achieved freezing of assay design for the cassette, which confirmed that the assay chemistry met the requirements for verification, validation, and pilot production. This milestone also led to more structured and forward-looking discussions with several potential partners. With freezing of assay design achieved for the cartridge, a strengthened balance sheet, and clearly defined next steps, we enter 2026 with a focus on final system verification, validation of production processes, pilot production of cartridges and instruments, followed by the initiation of the European multi-center clinical performance study. These activities represent the final and crucial steps before commercial launch in 2027. I would like to express my sincere thanks to our employees, our development and production partners, and our shareholders for their support during an important year for Prolight. We have significantly reduced technical risk, strengthened our IP position, delivered on our commitments, and strategically positioned the company for potential partnerships and future commercialization. With a clear and realistic timeline, we are now guiding Psyros through the final clinical performance study and further to market, creating value for patients, healthcare, society, and our shareholders.·12 t sittenGood that you take social responsibility and act as the devil's advocate, Fjalle. You have taken this task very seriously in a dozen other companies too, I have seen, almost as if one would think you profited from it 😂·11 t sittenWho knows, today one can make money on all sorts of things😂
- ·1 päivä sittenReport tomorrow. Exciting to hear if further development is on track without delays. Wish to hear more about clinical start-up and about possible partner discussions. The signals have probably been quite clear that the discussions have been taken to a new step and that they want a partner in the clinical process. It can be exciting going forward now. It is also the next 6 months ahead that will most likely be decisive for Prolight. An emission that Fjall here tries to scare some small investors with, I have little faith in, given the statements that have come from the management and simultaneously the insider purchases. Time will show·14 t sittenDystopian as usual from Fjall😊 everyone knows that biotech is risk and there are no guarantees for anything at all. There can be share issues and there can be agreements. Prolight must have more capital before they are finished, but it is typical that such companies either get a partner or are acquired when they have come as far as PD. We don't know this, but we know that there is great interest and we know that PD is beyond trivial talk. This is evident from what has been communicated. We also know that PD is unique with its product. I hope for the best but will be able to withstand a bucket of cold water for a while longer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
1 064
Myynti
Määrä
1 424
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 256 | AVA | EAG | ||
| 54 | AVA | EAG | ||
| 2 946 | AVA | NON | ||
| 154 | NON | NON | ||
| 10 | AVA | NON |
Ylin
20VWAP
Alin
17,04VaihtoMäärä
0,4 21 408
VWAP
Ylin
20Alin
17,04VaihtoMäärä
0,4 21 408
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 12 031 | 6 147 | +5 884 | 3 719 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| EAG | 0 | 609 | −609 | 0 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 116 | 5 010 | −4 894 | 114 |
| Svenska Handelsbanken AB | 1 898 | 3 172 | −1 274 | 463 |
| Nordnet Bank AB | 5 784 | 6 470 | −686 | 154 |
| EAG | 0 | 609 | −609 | 0 |
| Carnegie Investment Bank AB | 229 | 0 | +229 | 0 |
| Mangold Fondkommission AB | 1 350 | 0 | +1 350 | 0 |